AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Biology & Medicine Article
PDF (3.6 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy

Department of General Surgery of Ruijin Hospital, Shanghai Institute of Digestive Surgery, and Shanghai Key Laboratory for Gastric Neoplasms, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, China
Show Author Information

Abstract

Malignant tumors are complex structures composed of cancer cells and tumor microenvironmental cells. In this complex structure, cells cross-talk and interact, thus jointly promoting cancer development and metastasis. Recently, immunoregulatory molecule-based cancer immunotherapy has greatly improved treatment efficacy for solid cancers, thus enabling some patients to achieve persistent responses or cure. However, owing to the development of drug-resistance and the low response rate, immunotherapy against the available targets PD-1/PD-L1 or CTLA-4 has limited benefits. Although combination therapies have been proposed to enhance the response rate, severe adverse effects are observed. Thus, alternative immune checkpoints must be identified. The SIGLECs are a family of immunoregulatory receptors (known as glyco-immune checkpoints) discovered in recent years. This review systematically describes the molecular characteristics of the SIGLECs, and discusses recent progress in areas including synthetic ligands, monoclonal antibody inhibitors, and Chimeric antigen receptor T (CAR-T) cells, with a focus on available strategies for blocking the sialylated glycan-SIGLEC axis. Targeting glyco-immune checkpoints can expand the scope of immune checkpoints and provide multiple options for new drug development.

Keywords

SIGLECsialylated glycanglyco-immune checkpointhigh affinity SIGLEC-ligandsanti-SIGLEC antibodies

References

1

Shan Q, Takabatake K, Kawai H, Oo MW, Sukegawa S, Fujii M, et al. Crosstalk between cancer and different cancer stroma subtypes promotes the infiltration of tumor-associated macrophages into the tumor microenvironment of oral squamous cell carcinoma. Int J Oncol. 2022; 60: 78.
Crossref Google Scholar
2

Xuan W, Khan F, James CD, Heimberger AB, Lesniak MS, Chen P. Circadian regulation of cancer cell and tumor microenvironment crosstalk. Trends Cell Biol. 2021; 31: 940-50.
Crossref Google Scholar
3

Xu H, Li D, Ma J, Zhao Y, Xu L, Tian R, et al. The IL-33/ST2 axis affects tumor growth by regulating mitophagy in macrophages and reprogramming their polarization. Cancer Biol Med. 2021; 18: 172-83.
Crossref Google Scholar
4

Mise Y, Hamanishi J, Daikoku T, Takamatsu S, Miyamoto T, Taki M, et al. Immunosuppressive tumor microenvironment in uterine serous carcinoma via CCL7 signal with myeloid-derived suppressor cells. Carcinogenesis. 2022; 43: 647-58.
Crossref Google Scholar
5

Falcomata C, Barthel S, Schneider G, Rad R, Schmidt-Supprian M, Saur D. Context-specific determinants of the immunosuppressive tumor microenvironment in pancreatic cancer. Cancer Discov. 2023; 13: 278-97.
Crossref Google Scholar
6

Ariyan CE, Brady MS, Siegelbaum RH, Hu J, Bello DM, Rand J, et al. Robust antitumor responses result from local chemotherapy and CTLA-4 blockade. Cancer Immunol Res. 2018; 6: 189-200.
Crossref Google Scholar
7

Guo Z, Yuan Y, Chen C, Lin J, Ma Q, Liu G, et al. Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer. NPJ Precis Oncol. 2022; 6: 34.
Crossref Google Scholar
8

Zhao Q, Tong J, Liu X, Li S, Chen D, Miao L. Reversing resistance to immune checkpoint inhibitor by adding recombinant human adenovirus type 5 in a patient with small cell lung cancer with promoted immune infiltration: a case report. J Cancer Res Clin Oncol. 2022; 148: 1269-73.
Crossref Google Scholar
9

Dobosz P, Stepien M, Golke A, Dzieciatkowski T. Challenges of the immunotherapy: perspectives and limitations of the immune checkpoint inhibitor treatment. Int J Mol Sci. 2022; 23: 2847.
Crossref Google Scholar
10

Gray MA, Stanczak MA, Mantuano NR, Xiao H, Pijnenborg JFA, Malaker SA, et al. Targeted glycan degradation potentiates the anticancer immune response in vivo. Nat Chem Biol. 2020; 16: 1376-84.
Crossref Google Scholar
11

Yu Y. Multi-target combinatory strategy to overcome tumor immune escape. Front Med. 2022; 16: 208-15.
Crossref Google Scholar
12

Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, von Gunten S, et al. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J Clin Invest. 2018; 128: 4912-23.
Crossref Google Scholar
13

Macauley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol. 2014; 14: 653-66.
Crossref Google Scholar
14

Lenza MP, Atxabal U, Oyenarte I, Jimenez-Barbero J, ErenoOrbea J. Current status on therapeutic molecules targeting Siglec receptors. Cells. 2020; 9: 2691.
Crossref Google Scholar
15

Adams OJ, Stanczak MA, von Gunten S, Laubli H. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer. Glycobiology. 2018; 28: 640-7.
Crossref Google Scholar
16

Lanier LL, Bakker AB. The ITAM-bearing transmembrane adaptor DAP12 in lymphoid and myeloid cell function. Immunol Today. 2000; 21: 611-4.
Crossref Google Scholar
17

Vuchkovska A, Glanville DG, Scurti GM, Nishimura MI, White P, Ulijasz AT, et al. Siglec-5 is an inhibitory immune checkpoint molecule for human T cells. Immunology. 2022; 166: 238-48.
Crossref Google Scholar
18

Gonzalez-Gil A, Schnaar RL. Siglec ligands. Cells. 2021; 10: 1260.
Crossref Google Scholar
19

Ruffin N, Gea-Mallorqui E, Brouiller F, Jouve M, Silvin A, See P, et al. Constitutive Siglec-1 expression confers susceptibility to HIV-1 infection of human dendritic cell precursors. Proc Natl Acad Sci U S A. 2019; 116: 21685-93.
Crossref Google Scholar
20

Hernandez-Caselles T, Martinez-Esparza M, Perez-Oliva AB, Quintanilla-Cecconi AM, Garcia-Alonso A, Alvarez-Lopez DM, et al. A study of CD33(Siglec-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. J Leukoc Biol. 2006; 79: 46-58.
Crossref Google Scholar
21

Schwarz F, Landig CS, Siddiqui S, Secundino I, Olson J, Varki N, et al. Paired Siglec receptors generate opposite inflammatory responses to a human-specific pathogen. EMBO J. 2017; 36: 751-60.
Crossref Google Scholar
22

Yamanaka M, Kato Y, Angata T, Narimatsu H. Deletion polymorphism of Siglec14 and its functional implications. Glycobiology. 2009; 19: 841-6.
Crossref Google Scholar
23

Jetani H, Navarro-Bailon A, Maucher M, Frenz S, Verbruggen C, Yeguas A, et al. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. Blood. 2021; 138: 1830-42.
Crossref Google Scholar
24

Yang L, Feng Y, Wang S, Jiang S, Tao L, Li J, et al. Siglec-7 is an indicator of natural killer cell function in acute myeloid leukemia. Int Immunopharmacol. 2021; 99: 107965.
Crossref Google Scholar
25

Haas Q, Markov N, Muerner L, Rubino V, Benjak A, Haubitz M, et al. Siglec-7 represents a glyco-immune checkpoint for nonexhausted effector memory CD8+ T cells with high functional and metabolic capacities. Front Immunol. 2022; 13: 996746.
Crossref Google Scholar
26

Haas Q, Boligan KF, Jandus C, Schneider C, Simillion C, Stanczak MA, et al. Siglec-9 regulates an effector memory CD8(+) T-cell subset that congregates in the melanoma tumor microenvironment. Cancer Immunol Res. 2019; 7: 707-18.
Crossref Google Scholar
27

Zhang C, Zhang J, Liang F, Guo H, Gao S, Yang F, et al. Innate immune checkpoint Siglec10 in cancers: mining of comprehensive omics data and validation in patient samples. Front Med. 2022; 16: 596-609.
Crossref Google Scholar
28

Wang X, Chow R, Deng L, Anderson D, Weidner N, Godwin AK, et al. Expression of Siglec-11 by human and chimpanzee ovarian stromal cells, with uniquely human ligands: implications for human ovarian physiology and pathology. Glycobiology. 2011; 21: 1038-48.
Crossref Google Scholar
29

Mitra N, Banda K, Altheide TK, Schaffer L, Johnson-Pais TL, Beuten J, et al. Siglec12, a human-specific segregating (pseudo) gene, encodes a signaling molecule expressed in prostate carcinomas. J Biol Chem. 2011; 286: 23003-11.
Crossref Google Scholar
30

Tsai CM, Riestra AM, Ali SR, Fong JJ, Liu JZ, Hughes G, et al. Siglec-14 enhances NLRP3-inflammasome activation in macrophages. J Innate Immun. 2020; 12: 333-43.
Crossref Google Scholar
31

Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019; 25: 656-66.
Crossref Google Scholar
32

Fujiwara Y, Saito Y, Shiota T, Cheng P, Ikeda T, Ohnishi K, et al. Natural compounds that regulate lymph node sinus macrophages: inducing an anti-tumor effect by regulating macrophage activation. J Clin Exp Hematop. 2018; 58: 17-23.
Crossref Google Scholar
33

Di Carluccio C, Forgione RE, Montefiori M, Civera M, Sattin S, Smaldone G, et al. Behavior of glycolylated sialoglycans in the binding pockets of murine and human CD22. i Science. 2021; 24: 101998.
Crossref Google Scholar
34

Blixt O, Collins BE, van den Nieuwenhof IM, Crocker PR, Paulson JC. Sialoside specificity of the Siglec family assessed using novel multivalent probes: identification of potent inhibitors of myelinassociated glycoprotein. J Biol Chem. 2003; 278: 31007-19.
Crossref Google Scholar
35

Brinkman-Van der Linden EC, Angata T, Reynolds SA, Powell LD, Hedrick SM, Varki A. CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in mice. Mol Cell Biol. 2003; 23: 4199-206.
Crossref Google Scholar
36

Bhattacherjee A, Rodrigues E, Jung J, Luzentales-Simpson M, Enterina JR, Galleguillos D, et al. Repression of phagocytosis by human CD33 is not conserved with mouse CD33. Commun Biol. 2019; 2: 450.
Crossref Google Scholar
37

McMillan SJ, Sharma RS, Richards HE, Hegde V, Crocker PR. Siglec-E promotes beta2-integrin-dependent NADPH oxidase activation to suppress neutrophil recruitment to the lung. J Biol Chem. 2014; 289: 20370-6.
Crossref Google Scholar
38

Siddiqui S, Schwarz F, Springer S, Khedri Z, Yu H, Deng L, et al. Studies on the detection, expression, glycosylation, dimerization, and ligand binding properties of mouse Siglec-E. J Biol Chem. 2017; 292: 1029-37.
Crossref Google Scholar
39

Yu Z, Maoui M, Wu L, Banville D, Shen S. mSiglec-E, a novel mouse CD33-related Siglec (sialic acid-binding immunoglobulinlike lectin) that recruits Src homology 2(SH2)-domain-containing protein tyrosine phosphatases SHP-1 and SHP-2. Biochem J. 2001; 353: 483-92.
Crossref Google Scholar
40

Laubli H, Pearce OM, Schwarz F, Siddiqui SS, Deng L, Stanczak MA, et al. Engagement of myelomonocytic Siglecs by tumorassociated ligands modulates the innate immune response to cancer. Proc Natl Acad Sci U S A. 2014; 111: 14211-6.
Crossref Google Scholar
41

Smith BAH, Deutzmann A, Correa KM, Delaveris CS, Dhanasekaran R, Dove CG, et al. MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint. Proc Natl Acad Sci U S A. 2023; 120: e2215376120.
Crossref Google Scholar
42

Choi H, Ho M, Adeniji OS, Giron L, Bordoloi D, Kulkarni AJ, et al. Development of Siglec-9 blocking antibody to enhance anti-tumor immunity. Front Oncol. 2021; 11: 778989.
Crossref Google Scholar
43

Angata T, Hingorani R, Varki NM, Varki A. Cloning and characterization of a novel mouse Siglec, mSiglec-F: differential evolution of the mouse and human (CD33) Siglec-3-related gene clusters. J Biol Chem. 2001; 276: 45128-36.
Crossref Google Scholar
44

Aizawa H, Zimmermann N, Carrigan PE, Lee JJ, Rothenberg ME, Bochner BS. Molecular analysis of human Siglec-8 orthologs relevant to mouse eosinophils: identification of mouse orthologs of Siglec-5(m Siglec-F) and Siglec-10(m Siglec-G). Genomics. 2003; 82: 521-30.
Crossref Google Scholar
45

Mao H, Kano G, Hudson SA, Brummet M, Zimmermann N, Zhu Z, et al. Mechanisms of Siglec-F-induced eosinophil apoptosis: a role for caspases but not for SHP-1, SRc kinases, NADPH oxidase or reactive oxygen. PLo S One. 2013; 8: e68143.
Crossref Google Scholar
46

Bochner BS. Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors. Clin Exp Allergy. 2009; 39: 317-24.
Crossref Google Scholar
47

Zhang JQ, Biedermann B, Nitschke L, Crocker PR. The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils. Eur J Immunol. 2004; 34: 1175-84.
Crossref Google Scholar
48

Matsui M, Nagakubo D, Satooka H, Hirata T. A novel Siglec-F(+) neutrophil subset in the mouse nasal mucosa exhibits an activated phenotype and is increased in an allergic rhinitis model. Biochem Biophys Res Commun. 2020; 526: 599-606.
Crossref Google Scholar
49

Nycholat CM, Duan S, Knuplez E, Worth C, Elich M, Yao A, et al. A sulfonamide sialoside analogue for targeting Siglec-8 and-F on immune cells. J Am Chem Soc. 2019; 141: 14032-7.
Crossref Google Scholar
50

Zhang J, Raper A, Sugita N, Hingorani R, Salio M, Palmowski MJ, et al. Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors. Blood. 2006; 107: 3600-8.
Crossref Google Scholar
51

Blasius AL, Colonna M. Sampling and signaling in plasmacytoid dendritic cells: the potential roles of Siglec-H. Trends Immunol. 2006; 27: 255-60.
Crossref Google Scholar
52

Cao H, Lakner U, de Bono B, Traherne JA, Trowsdale J, Barrow AD. Siglec16 encodes a DAP12-associated receptor expressed in macrophages that evolved from its inhibitory counterpart Siglec11 and has functional and non-functional alleles in humans. Eur JImmunol. 2008; 38: 2303-15.
Crossref Google Scholar
53

Soares CO, Grosso AS, Ereno-Orbea J, Coelho H, Marcelo F. Molecular recognition insights of sialic acid glycans by distinct receptors unveiled by NMR and molecular modeling. Front Mol Biosci. 2021; 8: 727847.
Crossref Google Scholar
54

Tamada Y, Nomura H, Aoki D, Irimura T. A possible inhibitory role of sialic acid on MUC1 in peritoneal dissemination of clear celltype ovarian cancer cells. Molecules 2021; 26: 5962.
Crossref Google Scholar
55

Varki A, Cummings RD, Esko JD, Stanley P, Hart GW, Aebi M, et al. Essentials of glycobiology. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2022.
56

Gonzalez-Gil A, Li TA, Kim J, Schnaar RL. Human sialoglycan ligands for immune inhibitory Siglecs. Mol Aspects Med. 2022; 90: 101110.
Crossref Google Scholar
57

Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007; 7: 255-66.
Crossref Google Scholar
58

Rodrigues E, Jung J, Park H, Loo C, Soukhtehzari S, Kitova EN, et al. A versatile soluble siglec scaffold for sensitive and quantitative detection of glycan ligands. Nat Commun. 2020; 11: 5091.
Crossref Google Scholar
59

Movsisyan LD, Macauley MS. Structural advances of Siglecs: insight into synthetic glycan ligands for immunomodulation. Org Biomol Chem. 2020; 18: 5784-97.
Crossref Google Scholar
60

Suematsu R, Miyamoto T, Saijo S, Yamasaki S, Tada Y, Yoshida H, et al. Identification of lipophilic ligands of Siglec5 and-14that modulate innate immune responses. J Biol Chem. 2019; 294: 16776-88.
Crossref Google Scholar
61

Fong JJ, Sreedhara K, Deng L, Varki NM, Angata T, Liu Q, et al. Immunomodulatory activity of extracellular Hsp70 mediated via paired receptors Siglec-5 and Siglec-14. EMBO J. 2015; 34: 2775-88.
Crossref Google Scholar
62

Carlin AF, Chang YC, Areschoug T, Lindahl G, Hurtado-Ziola N, King CC, et al. Group B streptococcus suppression of phagocyte functions by protein-mediated engagement of human Siglec-5. JExp Med. 2009; 206: 1691-9.
Crossref Google Scholar
63

Fong JJ, Tsai CM, Saha S, Nizet V, Varki A, Bui JD. Siglec-7 engagement by GBS beta-protein suppresses pyroptotic cell death of natural killer cells. Proc Natl Acad Sci U S A. 2018; 115: 10410-5.
Crossref Google Scholar
64

Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019; 572: 392-6.
Crossref Google Scholar
65

Chang LY, Liang SY, Lu SC, Tseng HC, Tsai HY, Tang CJ, et al. Molecular basis and role of Siglec-7 ligand expression on chronic lymphocytic leukemia B cells. Front Immunol. 2022; 13: 840388.
Crossref Google Scholar
66

van Houtum EJH, Bull C, Cornelissen LAM, Adema GJ. Siglec signaling in the tumor microenvironment. Front Immunol. 2021; 12: 790317.
Crossref Google Scholar
67

Magesh S, Ando H, Tsubata T, Ishida H, Kiso M. High-affinity ligands of Siglec receptors and their therapeutic potentials. Curr Med Chem. 2011; 18: 3537-50.
Crossref Google Scholar
68

Dobie C, Skropeta D. Insights into the role of sialylation in cancer progression and metastasis. Br J Cancer. 2021; 124: 76-90.
Crossref Google Scholar
69

Scara S, Bottoni P, Scatena R. CA 19-9: biochemical and clinical aspects. Adv Exp Med Biol. 2015; 867: 247-60.
Crossref Google Scholar
70

Rodriguez E, Boelaars K, Brown K, Eveline Li RJ, Kruijssen L, Bruijns SCM, et al. Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. Nat Commun. 2021; 12: 1270.
Crossref Google Scholar
71

Li B, Zhang B, Wang X, Zeng Z, Huang Z, Zhang L, et al. Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis. Oncoimmunology. 2020; 9: 1807291.
Crossref Google Scholar
72

Zhang Y, Ye G, Yang Q, Zheng B, Zhang G, Hu Y, et al. Landscape of exitrons in gastric cancer. EBio Medicine. 2022; 84: 104272.
Crossref Google Scholar
73

Wang JB, Li P, Liu XL, Zheng QL, Ma YB, Zhao YJ, et al. An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer. Nat Commun. 2020; 11: 6352.
Crossref Google Scholar
74

Yu Y, Wei C. A powerful HUPAN on a pan-genome study: significance and perspectives. Cancer Biol Med. 2020; 17: 1-5.
Crossref Google Scholar
75

Duan Z, Qiao Y, Lu J, Lu H, Zhang W, Yan F, et al. HUPAN: a pangenome analysis pipeline for human genomes. Genome Biol. 2019; 20: 149.
Crossref Google Scholar
76

Yu Y, Zhang Z, Dong X, Yang R, Duan Z, Xiang Z, et al. Pangenomic analysis of Chinese gastric cancer. Nat Commun. 2022; 13: 5412.
Crossref Google Scholar
77

Zhang H, Xie Y, Hu Z, Yu H, Xie X, Ye Y, et al. Integrative analysis of the expression of SIGLEC family members in lung adenocarcinoma via data mining. Front Oncol. 2021; 11: 608113.
Crossref Google Scholar
78

Bull C, Heise T, Adema GJ, Boltje TJ. Sialic acid mimetics to target the Sialic acid-Siglec axis. Trends Biochem Sci. 2016; 41: 519-31.
Crossref Google Scholar
79

Bull C, Nason R, Sun L, Van Coillie J, Madriz Sorensen D, Moons SJ, et al. Probing the binding specificities of human Siglecs by cell-based glycan arrays. Proc Natl Acad Sci U S A. 2021; 118: e2026102118.
Crossref Google Scholar
80

Wang J, Manni M, Barenwaldt A, Wieboldt R, Kirchhammer N, Ivanek R, et al. Siglec receptors modulate dendritic cell activation and antigen presentation to T cells in cancer. Front Cell Dev Biol. 2022; 10: 828916.
Crossref Google Scholar
81

Duan S, Paulson JC. Siglecs as immune cell checkpoints in disease. Annu Rev Immunol. 2020; 38: 365-95.
Crossref Google Scholar
82

Hudak JE, Canham SM, Bertozzi CR. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nat Chem Biol. 2014; 10: 69-75.
Crossref Google Scholar
83

Ohira S, Yasuda Y, Tomita I, Kitajima K, Takahashi T, Sato C, et al. Synthesis of end-functionalized glycopolymers containing alpha(2,8) disialic acids via pi-allyl nickel catalyzed coordinating polymerization and their interaction with Siglec-7. Chem Commun (Camb). 2017; 53: 553-6.
Crossref Google Scholar
84

Yamaguchi S, Yoshimura A, Yasuda Y, Mori A, Tanaka H, Takahashi T, et al. Chemical synthesis and evaluation of a disialic acidcontaining dextran polymer as an inhibitor for the interaction between Siglec 7 and its ligand. Chembiochem. 2017; 18: 1194-203.
Crossref Google Scholar
85

Ohta M, Ishida A, Toda M, Akita K, Inoue M, Yamashita K, et al. Immunomodulation of monocyte-derived dendritic cells through ligation of tumor-produced mucins to Siglec-9. Biochem Biophys Res Commun. 2010; 402: 663-9.
Crossref Google Scholar
86

Laubli H, Kawanishi K, George Vazhappilly C, Matar R, Merheb M, Sarwar Siddiqui S. Tools to study and target the Siglec-sialic acid axis in cancer. FEBS J. 2021; 288: 6206-25.
Crossref Google Scholar
87

Nycholat CM, Rademacher C, Kawasaki N, Paulson JC. In silicoaided design of a glycan ligand of sialoadhesin for in vivo targeting of macrophages. J Am Chem Soc. 2012; 134: 15696-9.
Crossref Google Scholar
88

Blixt O, Han S, Liao L, Zeng Y, Hoffmann J, Futakawa S, et al. Sialoside analogue arrays for rapid identification of high affinity siglec ligands. J Am Chem Soc. 2008; 130: 6680-1.
Crossref Google Scholar
89

Rillahan CD, Schwartz E, Rademacher C, McBride R, Rangarajan J, Fokin VV, et al. On-chip synthesis and screening of a sialoside library yields a high affinity ligand for Siglec-7. ACS Chem Biol. 2013; 8: 1417-22.
Crossref Google Scholar
90

Briard JG, Jiang H, Moremen KW, Macauley MS, Wu P. Cellbased glycan arrays for probing glycan-glycan binding protein interactions. Nat Commun. 2018; 9: 880.
Crossref Google Scholar
91

Bull C, Heise T, van Hilten N, Pijnenborg JF, Bloemendal VR, Gerrits L, et al. Steering Siglec-sialic acid interactions on living cells using bioorthogonal chemistry. Angew Chem Int Ed Engl. 2017; 56: 3309-13.
Crossref Google Scholar
92

Chen WC, Completo GC, Sigal DS, Crocker PR, Saven A, Paulson JC. In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood. 2010; 115: 4778-86.
Crossref Google Scholar
93

Macauley MS, Pfrengle F, Rademacher C, Nycholat CM, Gale AJ, von Drygalski A, et al. Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis. J Clin Invest. 2013; 123: 3074-83.
Crossref Google Scholar
94

Duan S, Koziol-White CJ, Jester WF, Jr., Smith SA, Nycholat CM, Macauley MS, et al. CD33 recruitment inhibits Ig E-mediated anaphylaxis and desensitizes mast cells to allergen. J Clin Invest. 2019; 129: 1387-401.
Crossref Google Scholar
95

Wang XW, Lang SY, Tian YP, Zhang JH, Yan X, Fang ZH, et al. Glycoengineering of natural killer cells with CD22 ligands for enhanced anticancer immunotherapy. ACS Central Sci. 2020; 6: 382-9.
Crossref Google Scholar
96

Hong S, Yu C, Wang P, Shi Y, Cao W, Cheng B, et al. Glycoengineering of NK cells with glycan ligands of CD22 and selectins for B-cell lymphoma therapy. Angew Chem Int Ed Engl. 2021; 60: 3603-10.
Crossref Google Scholar
97

Delaveris CS, Chiu SH, Riley NM, Bertozzi CR. Modulation of immune cell reactivity with cis-binding Siglec agonists. P Natl Acad Sci USA. 2021; 118: e2012408118.
Crossref Google Scholar
98

Delaveris CS, Wilk AJ, Riley NM, Stark JC, Yang SS, Rogers AJ, et al. Synthetic Siglec-9 agonists inhibit neutrophil activation associated with COVID-19. ACS Cent Sci. 2021; 7: 650-7.
Crossref Google Scholar
99

Kelm S, Gerlach J, Brossmer R, Danzer CP, Nitschke L. The ligand-binding domain of CD22 is needed for inhibition of the Bcell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound. J Exp Med. 2002; 195: 1207-13.
Crossref Google Scholar
100

Rillahan CD, Macauley MS, Schwartz E, He Y, McBride R, Arlian BM, et al. Disubstituted sialic acid ligands targeting Siglecs CD33 and CD22 associated with myeloid leukaemias and B cell lymphomas. Chem Sci. 2014; 5: 2398-406.
Crossref Google Scholar
101

Yu H, Gonzalez-Gil A, Wei Y, Fernandes SM, Porell RN, Vajn K, et al. Siglec-8 and Siglec-9 binding specificities and endogenous airway ligand distributions and properties. Glycobiology. 2017; 27: 657-68.
Crossref Google Scholar
102

Rillahan CD, Schwartz E, McBride R, Fokin VV, Paulson JC. Click and pick: identification of sialoside analogues for siglec-based cell targeting. Angew Chem Int Ed Engl. 2012; 51: 11014-8.
Crossref Google Scholar
103

Murugesan G, Correia VG, Palma AS, Chai W, Li C, Feizi T, et al. Siglec-15 recognition of sialoglycans on tumor cell lines can occur independently of sialyl Tn antigen expression. Glycobiology. 2021; 31: 44-54.
Crossref Google Scholar
104

Cyr MG, Mhibik M, Qi J, Peng H, Chang J, Gaglione EM, et al. Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia. J Immunother Cancer. 2022; 10: e004850.
Crossref Google Scholar
105

Xiao X, Peng Y, Wang Z, Zhang L, Yang T, Sun Y, et al. A novel immune checkpoint Siglec-15 antibody inhibits LUAD by modulating mφpolarization in TME. Pharmacol Res. 2022; 181: 106269.
Crossref Google Scholar
106

He F, Wang N, Li J, He L, Yang Z, Lu J, et al. High affinity monoclonal antibody targeting Siglec-15 for cancer immunotherapy. J Clin Transl Res. 2021; 7: 739-49.
Google Scholar
107

Wu J, Peng J, Zhou Y, Zhang R, Wang Z, Hu N, et al. Screening and identification of a novel anti-siglec-15 human antibody 3F1 and relevant antitumor activity. Mol Pharmacol. 2022; 102: 161-71.
Crossref Google Scholar
108

Friedrich M, Henn A, Raum T, Bajtus M, Matthes K, Hendrich L, et al. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014; 13: 1549-57.
Crossref Google Scholar
109

Baron J, Wang ES. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018; 11: 549-59.
Crossref Google Scholar
110

Lamba JK, Chauhan L, Shin M, Loken MR, Pollard JA, Wang YC, et al. CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase Ⅲ children’s oncology group trial AAML0531. J Clin Oncol. 2017; 35: 2674-82.
Crossref Google Scholar
111

Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Sauer T, et al. Rationale and design of the 2 by 2 factorial design Gn G-trial: a randomized phase-Ⅲ study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML. Trials. 2021; 22: 765.
Crossref Google Scholar
112

Kantarjian HM, De Angelo DJ, Stelljes M, Liedtke M, Stock W, Gokbuget N, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019; 125: 2474-87.
Crossref Google Scholar
113

Toussaint K, Appert-Collin A, Morjani H, Albrecht C, Sartelet H, Romier-Crouzet B, et al. Neuraminidase-1: a sialidase involved in the development of cancers and metabolic diseases. Cancers (Basel). 2022; 14: 4868.
Crossref Google Scholar
114

Lillehoj EP, Luzina IG, Atamas SP. Mammalian neuraminidases in immune-mediated diseases: mucins and beyond. Front Immunol. 2022; 13: 883079.
Crossref Google Scholar
115

Xiao H, Woods EC, Vukojicic P, Bertozzi CR. Precision glycocalyx editing as a strategy for cancer immunotherapy. Proc Natl Acad Sci U S A. 2016; 113: 10304-9.
Crossref Google Scholar
116

Stanczak MA, Rodrigues Mantuano N, Kirchhammer N, Sanin DE, Jacob F, Coelho R, et al. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. Sci Transl Med. 2022; 14: eabj1270.
Crossref Google Scholar
117

Wu Y, Zhang T, Zhang X, Gao Q. Decoding the complexity of metastasis. Cancer Biol Med. 2022; 19: 284-8.
Crossref Google Scholar
118

Wissfeld J, Werner A, Yan X, Ten Bosch N, Cui G. Metabolic regulation of immune responses to cancer. Cancer Biol Med. 2022; 19: 1528-42.
Crossref Google Scholar
119

Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022; 21: 799-820.
Crossref Google Scholar
120

Xue R, Zhang Q, Cao Q, Kong R, Xiang X, Liu H, et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature. 2022; 612: 141-7.
Crossref Google Scholar
121

Raftopoulou S, Valadez-Cosmes P, Mihalic ZN, Schicho R, Kargl J. Tumor-mediated neutrophil polarization and therapeutic implications. Int J Mol Sci. 2022; 23: 3218.
Crossref Google Scholar
122

Secundino I, Lizcano A, Roupe KM, Wang X, Cole JN, Olson J, et al. Host and pathogen hyaluronan signal through human Siglec-9 to suppress neutrophil activation. J Mol Med (Berl). 2016; 94: 219-33.
Crossref Google Scholar
123

Huang J, Li M, Mei B, Li J, Zhu Y, Guo Q, et al. Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity. J Transl Med. 2022; 20: 496.
Crossref Google Scholar
124

Liu B, Song Y, Liu D. Clinical trials of CAR-T cells in China. JHematol Oncol. 2017; 10: 166.
Crossref Google Scholar
125

Liu D. Cancer biomarkers for targeted therapy. Biomark Res. 2019; 7: 25.
Crossref Google Scholar
126
Roddie C, Lekakis LJ, Marzolini MAV, Ramakrishnan A, Zhang Y, Hu Y, et al. Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B cell lymphoma. Blood. 2023. doi: 10.1182/blood.2022018598. Online ahead of print.
Crossref
127

Dorsett KA, Marciel MP, Hwang J, Ankenbauer KE, Bhalerao N, Bellis SL. Regulation of ST6GAL1 sialyltransferase expression in cancer cells. Glycobiology. 2021; 31: 530-9.
Crossref Google Scholar
128

Smithson M, Irwin R, Williams G, Alexander KL, Smythies LE, Nearing M, et al. Sialyltransferase ST6GAL-1 mediates resistance to chemoradiation in rectal cancer. J Biol Chem. 2022; 298: 101594.
Crossref Google Scholar
129

Zhang X, Xu CH, Mo J, Zheng XJ, Chen YF, Yang AQ, et al. Selfassembled core-shell nanoscale coordination polymer nanoparticles carrying a sialyltransferase inhibitor for cancer metastasis inhibition. ACS Appl Mater Interfaces. 2023; 15: 7713-24.
Crossref Google Scholar
130

Tomioka Y, Morimatsu M, Nishijima K, Usui T, Yamamoto S, Suyama H, et al. A soluble form of Siglec-9 provides an antitumor benefit against mammary tumor cells expressing MUC1 in transgenic mice. Biochem Biophys Res Commun. 2014; 450: 532-7.
Crossref Google Scholar
131

Ono E, Uede T. Implication of soluble forms of cell adhesion molecules in infectious disease and tumor: insights from transgenic animal models. Int J Mol Sci. 2018; 19: 239.
Crossref Google Scholar
132

Huang PJ, Low PY, Wang I, Hsu SD, Angata T. Soluble Siglec-14 glycan-recognition protein is generated by alternative splicing and suppresses myeloid inflammatory responses. J Biol Chem. 2018; 293: 19645-58.
Crossref Google Scholar
Cancer Biology & Medicine
Volume 20 Issue 5,
May 2023
Pages 369-384
DOI: 10.20892/j.issn.2095-3941.2023.0046
Cite this article:
Yu Y, Peng W. Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy. Cancer Biology & Medicine, 2023, 20(5): 369-384. https://doi.org/10.20892/j.issn.2095-3941.2023.0046

546

Views

21

Downloads

1

Crossref

4

Web of Science

4

Scopus

Altmetrics
Received: 09 February 2023
Accepted: 27 March 2023
Published: 05 June 2023
©2023 Cancer Biology & Medicine.

Creative Commons Attribution-NonCommercial 4.0 International License
Return